Paper Details
- Home
- Paper Details
Efficacy and safety of cilostazol-based triple antiplatelet therapy compared with clopidogrel-based dual antiplatelet therapy in patients with acute ST-elevation myocardial infarction undergoing percutaneous coronary intervention: A multicenter, randomized, open-label, phase 4 trial.
Author: AhnJihun, ByunJae Kyeong, ChaJin Ah, ChenKang-Yin, ChoiByoung Geol, ChoiCheol Ung, ChoiSe Yeon, ChoiWoong Gil, HerAe-Young, HyunSu Jin, JeongMyung Ho, KimBae Keun, KimMin Woong, KimWoohyeun, KimYong Hoon, LeeJae Beom, LeeSeung Jin, ParkChang Gyu, ParkJi Young, ParkSang Min, ParkSoohyung, RhaSeung-Woon, SeoJae-Bin, ShinEun-Seok
Original Abstract of the Article :
Previous studies reported that compared to conventional dual antiplatelet therapy (DAT; aspirin + clopidogrel), triple antiplatelet therapy (TAT), involving the addition of cilostazol to DAT, had better clinical outcomes in patients with ST-elevation myocardial infarction (STEMI). However, the optim...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1016/j.ahj.2023.06.015
データ提供：米国国立医学図書館（NLM）
Cilostazol-Based Triple Antiplatelet Therapy in STEMI
This research explores a critical area of cardiovascular care, investigating the efficacy and safety of cilostazol-based triple antiplatelet therapy (TAT) in patients with acute ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). The study, a multicenter randomized open-label phase 4 trial, compared TAT with conventional dual antiplatelet therapy (DAT). The study aimed to determine the optimal duration of TAT, seeking to optimize patient outcomes after STEMI.
Improving Outcomes After STEMI: The Role of Triple Antiplatelet Therapy
The research suggests that TAT, involving the addition of cilostazol to DAT, could potentially improve clinical outcomes in STEMI patients undergoing PCI. This finding underscores the potential benefits of exploring different antiplatelet therapies to optimize treatment strategies for this serious condition. It's like discovering a new oasis in a desert of treatment options, potentially offering a more effective approach to managing STEMI and improving patient outcomes.
Cardiovascular Care: Seeking Optimized Treatment Strategies
This study highlights the importance of ongoing research to optimize treatment strategies for STEMI patients. The research explores the potential benefits of TAT, suggesting that further investigation could lead to more personalized and effective therapies for this critical condition. It's like embarking on a journey through a vast desert of treatment options, seeking the most effective and safe path to navigate the challenges of STEMI.
Dr.Camel's Conclusion
This study provides valuable insights into the potential of cilostazol-based triple antiplatelet therapy in STEMI patients undergoing PCI. The findings suggest that this approach could potentially improve clinical outcomes, offering a promising avenue for future research to explore and optimize treatment strategies for this serious condition. It's a reminder that the pursuit of better cardiovascular care is an ongoing journey, with new discoveries and innovations constantly emerging.
Date :
- Date Completed n.d.
- Date Revised 2023-10-12
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.